Evidence map›Paper›PMID 42147443›Full record

ArticleMolecular therapy. Advances2026

A single-cell multi-omics assay for simultaneous measurement of vector copy number and protein expression in CAR T cells.

Yilong Yang, Saurabh Parikh, Chieh-Yuan Li, Lindsey Murphy, Khushali Patel, Qawer Ayaz, Mahir Mohiuddin, John T Elliott, Hua-Jun He, Zhiyong He and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yilong YangMission Bio, 300 Utah Avenue, Suite 210, South San Francisco, CA 94080, USA.
Saurabh ParikhMission Bio, 300 Utah Avenue, Suite 210, South San Francisco, CA 94080, USA.
Chieh-Yuan LiMission Bio, 300 Utah Avenue, Suite 210, South San Francisco, CA 94080, USA.
Lindsey MurphyCity of Hope, Duarte, CA 91010, USA.
Khushali PatelMission Bio, 300 Utah Avenue, Suite 210, South San Francisco, CA 94080, USA.
Qawer AyazMission Bio, 300 Utah Avenue, Suite 210, South San Francisco, CA 94080, USA.
Mahir MohiuddinNational Institute of Standards and Technology, Gaithersburg, MD 20899, USA.
John T ElliottNational Institute of Standards and Technology, Gaithersburg, MD 20899, USA.
Hua-Jun HeNational Institute of Standards and Technology, Gaithersburg, MD 20899, USA.
Zhiyong HeNational Institute of Standards and Technology, Gaithersburg, MD 20899, USA.
Samantha MaraghNational Institute of Standards and Technology, Gaithersburg, MD 20899, USA.
Benjamin SchroederMission Bio, 300 Utah Avenue, Suite 210, South San Francisco, CA 94080, USA.
Terry J FryChildren's Hospital Colorado, Aurora, CO 80045, USA.
Amanda WintersChildren's Hospital Colorado, Aurora, CO 80045, USA.
Shu WangMission Bio, 300 Utah Avenue, Suite 210, South San Francisco, CA 94080, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor T cell (CAR T) immunotherapies have transformed cancer treatment. These therapies typically involve lentiviral vector-mediated CAR gene integration, followed by reinfusion into patients, necessitating rigorous quality control. Critical parameters, including transduction efficiency and vector copy number (VCN), must be accurately quantified. However, conventional gene transfer assays lack the resolution to capture cellular heterogeneity, relying on bulk population averages or labor-intensive clonal outgrowth methods. In order to address these limitations, we have developed an end-to-end solution from panel design to data analysis pipeline for targeted single-cell interrogation of transgene copy number. We applied this single-cell protein + DNA multi-omics VCN workflow to analyze a bi-cistronic CD19xCD22 CAR T product. Our VCN analysis exhibited high sensitivity, specificity, and average VCN linearity, as validated by an orthogonal method. Additionally, it uniquely revealed the unprecedented single-cell resolution of the VCN distribution profile. Furthermore, we quantitatively measured surface protein expression for lineage assignment, which revealed differential transduction percentages and VCN distribution patterns across cell lineages (e.g., CD4+ and CD8+ T cells), providing insights into factors potentially influencing treatment outcomes. This single-cell genomic/proteomic workflow could be a powerful research tool with potential clinical applications to enhance our ability to deliver optimal CAR T products to patients.

Indexed as

CAR Tcell therapyDNA sequencinggene therapylentiviral vectorprotein sequencingsingle-cellVCN distributionvector copy numbervector transduction

Identifiers

PMID42147443
PMCPMC13175768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.